ADAP Advocacy issued the following press releases:
Counterfeit pill availability in the United States is increasing, including recent incidents involving HIV medications
WASHINGTON, D.C. (September 13, 2023) - WASHINGTON, D.C. – ADAP Advocacy, in collaboration with the Partnership for Safe Medicines (PSM), is calling for more awareness over counterfeit medicines in the United States. Data recently shared in the MMWR [Morbidity and Mortality Weekly Report] highlights a growing problem, which is potentially contributing to overdose deaths. Aside from some high-profile cases involving criminal enterprises pushing fake HIV medications, counterfeit pill availability is rising in the drug supply chain, but also the illicit drug market.
Senator’s Bipartisan Working Group on 340B issued request for information on how to improve accountability and transparency
WASHINGTON, D.C. (July 27, 2023) - WASHINGTON, D.C. – ADAP Advocacy, in collaboration with the Community Access National Network (CANN), submitted public comment in response to the Request for Information (RFI) issued by the Senator’s Bipartisan 340B Working Group seeking feedback on the 340B Drug Pricing Program. The recommendations submitted to the working group focus on returning the 340B Program to its legislative intent, rather than the program’s current trajectory which largely benefits providers over patients.
New Brand Reflects Renewed Focus on AIDS Drug Assistance Programs
WASHINGTON, D.C. (July 24, 2023) - The ADAP Advocacy Association today announced it has been rebranded to “ADAP Advocacy”, a move reflecting the organization’s renewed focus on the AIDS Drug Assistance Program (“ADAP”).The legal entity will remain the ADAP Advocacy Association.
On behalf of the ADAP Advocacy Association and Community Access National Network (CANN)
WASHINGTON, D.C. (May 24, 2023) - The ADAP Advocacy Association (aaa+®) and the Community Access National Network (CANN) issued the following joint statement in response to a series of hateful bills passed by the Florida Legislature and signed into law by Governor Ron DeSantis. The ADAP Advocacy Association and CANN are hereby adjoined to the formal travel advisories issued by the NAACP, League of United Latin American Citizens, and Equality Florida – calling Florida 'hostile' to Black Americans, people of color and LGBTQ+ individuals. Both organizations also are concerned Florida's politics is now hostile toward people living with HIV.
Highlighting its Commitment to Access, Information & Participation
WASHINGTON, D.C. (April 25, 2023) - The ADAP Advocacy Association (aaa+®) today released its 2022 Annual Report – which highlights the organization’s ongoing commitment to access, information and participation for patient advocacy designed to promote and protect the AIDS Drug Assistance Program ("ADAP"). The report is shared using an infographic format to capture the previous year's highlights.
Legislation puts common sense guidelines around insurance industry practice of "step therapy"
WASHINGTON, D.C. (April 18, 2023) - The ADAP Advocacy Association (aaa+®) today announced it joined over 200 patient and health care provider groups from across the country applauding the reintroduction of the legislation aimed at putting reasonable parameters around the insurance industry’s "step therapy" or "fail first" cost containment protocols. The Safe Step Act mirrors legislation passed in more than three dozen states across the country. When passed into law the legislation will bring similar patient protections to employer health plans that are regulated on the federal level.
ADAP Advocacy Association Tackles Counterfeit HIV Medicines
WASHINGTON, D.C. (April 6, 2023) - The ADAP Advocacy Association (aaa+®) participated in a digital policy briefing hosted by the Partnership for Safe Medicines (PSM) on recent supply chain breaks involving counterfeit, misbranded and substandard HIV medications. The digital policy briefing is part of the comprehensive PSM 118th Congress Counterfeit Drug Briefing – which also encompasses the dangers behind drug importation and online pharmacies.
Alliance reinforces the urgency for action today to ensure the long-term viability of the program for tomorrow
WASHINGTON, D.C. (March 28, 2023) - The ADAP Advocacy Association (aaa+®) today announced it has joined the Alliance to Save America’s 340B Program (ASAP 340B), which is a partnership of community health centers, patient, provider, and consumer advocates, and leaders from the biopharmaceutical industry working to ensure the 340B program supports true safety-net providers and the communities they serve. ASAP 340B reflects a growing chorus calling for accountability and transparency reforms.
Amicus Brief filed in suit to end policy that prohibits copay assistance from counting toward patients’ out-of-pocket spending
WASHINGTON, D.C. (February 23, 2023) - The ADAP Advocacy Association (aaa+®) today announced it joined 29 patient, provider, and consumer organizations representing a wide range of illnesses and health conditions filing an amicus brief in support of a case brought against the U.S. Department of Health and Human Services by the HIV+Hepatitis Policy Institute, the Diabetes Leadership Council, the Diabetes Patient Advocacy Coalition, and three patients.
Retreats designed to assemble key stakeholder groups to discuss pertinent issues facing people living with HIV/AIDS and other chronic health conditions
WASHINGTON, D.C. (January 25, 2023) - The ADAP Advocacy Association (aaa+®) today announced its 2023 Health Fireside Chats.